

Evidence for beneficial associations between Isoenergetic Macronutrient Exchanges and serum non-HDL cholesterol, a measure of all circulating atherogenic, apoB-containing lipoproteins

Article

Published Version

Creative Commons: Attribution 4.0 (CC-BY)

Open Access

Griffin, B. A. and Lovegrove, J. A. (2021) Evidence for beneficial associations between Isoenergetic Macronutrient Exchanges and serum non-HDL cholesterol, a measure of all circulating atherogenic, apoB-containing lipoproteins. *Journal of Nutrition*, 151 (8). pp. 2096-2098. ISSN 1541-6100 doi: <https://doi.org/10.1093/jn/nxab127> Available at <https://centaur.reading.ac.uk/99742/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.1093/jn/nxab127>

Publisher: American Society for Nutrition

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online

Evidence for Beneficial Associations between Isoenergetic Macronutrient Exchanges and Serum non-HDL Cholesterol, a Measure of All Circulating Atherogenic, apoB-Containing Lipoproteins

Bruce A Griffin¹ and Julie A Lovegrove^{2,3}

¹Department of Nutritional Sciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, United Kingdom;

²Hugh Sinclair Unit of Human Nutrition, Department of Food and Nutritional Sciences, University of Reading, Reading, Berkshire, United Kingdom; and ³Institute for Cardiovascular and Metabolic Research, Department of Food and Nutritional Sciences, University of Reading, Reading, Berkshire, United Kingdom

The replacement of SFAs with unsaturated fatty acids remains a cornerstone of current dietary guidelines to reduce risk of atherosclerotic cardiovascular disease (ASCVD) (1). Although much of the basis for this specific guideline rests on the lowering of serum LDL cholesterol, there is evidence to suggest that this dietary exchange may have an impact on other cardiometabolic risk factors (2,3). Low serum HDL cholesterol (<40 mg/dL) and elevated non-HDL cholesterol (>130 mg/dL) are relevant in this respect, the latter because it represents a measure of cholesterol in all circulating atherogenic, apoB-containing lipoproteins [VLDL, IDL, LDL, Lipoprotein (a), and lipoprotein remnants] (4). The response of serum LDL cholesterol to isoenergetic macronutrient exchanges has been well documented in meta-analyses and shown to occur in a dose-response fashion (5,6); there is, however, less evidence for the effects of these dietary exchanges on serum non-HDL cholesterol.

The study by Pinart et al. (7) in this issue of *The Journal of Nutrition* reports a study-level meta-analysis (or federated meta-analysis) in which the analysis was undertaken in each of the included studies separately, followed by a combination of all estimates and SEs using conventional study-level meta-analysis. The dietary exchange model involved the isoenergetic replacement of 5% of total energy from total carbohydrates with either total fat, SFAs, PUFAs, or MUFAs. Associations between these dietary exchanges and serum HDL and non-HDL cholesterol were examined in 5919 male and female (54%) participants, aged between 15 and 65 y, from 8 observational European studies. Five of these studies were longitudinal and 3 cross-sectional, in which data from a baseline or single follow-up visit were used in the dietary exchange model. The studies, which were predominantly German (5 of 8) with others from

Belgium, Italy, and Spain, were part of the European Nutritional Phenotype Assessment and Data Sharing Initiative. Dietary intake was assessed by a variety of validated, self-completed methods that were specific to each country. Data were examined primarily by virtual individual person data analysis, and a study-level meta-analysis general linear model to compare results in a secondary analysis.

In models adjusted for sex, age, smoking, and BMI, the replacement of carbohydrate with SFAs or PUFAs was shown to be unrelated to fasted HDL cholesterol, but associated with a higher and lower non-HDL cholesterol, respectively (SFAs: 1.94 mg/dL; 95% CI: 0.08, 3.79 mg/dL; $P = 0.04$; and PUFAs: -3.91 mg/dL; 95% CI: -6.98, -0.84 mg/dL; $P = 0.01$). In contrast, replacement of carbohydrate with either total fat or MUFAs was associated with a higher HDL cholesterol (total fat: 0.67 mg/dL; 95% CI: 0.40, 0.94 mg/dL; $P < 0.0001$; and MUFAs: 0.99 mg/dL; 95% CI: 0.37, 1.60 mg/dL; $P = 0.002$), but was unrelated to non-HDL cholesterol. Age was unrelated to these associations, and there was an inverse association between non-HDL cholesterol in men and the replacement of carbohydrate with MUFAs, although substantial heterogeneity in the data presumably precluded subgroup analysis. The replacement of 5% of energy from carbohydrates with total fats was more strongly associated with higher HDL cholesterol in women (0.84 mg/dL; 95% CI: 0.46, 1.21 mg/dL) than in men (0.44 mg/dL; 95% CI: 0.07, 0.82 mg/dL; P -interaction = 0.05).

The positive and potentially favorable associations between the replacement of carbohydrate with total fat or MUFAs and serum HDL cholesterol are consistent with the established effects of these dietary exchanges from meta-analyses of randomized controlled trials (RCTs) (5,6). The lack of association between replacing carbohydrate with total fat and non-HDL cholesterol could suggest that greater emphasis should be placed on fat quality, rather than quantity, for reducing cardiometabolic risk. A less consistent result with previous findings was the absence of significant associations between carbohydrate replacement with PUFAs or SFAs and HDL cholesterol. In meta-analyses of RCTs, both LDL and HDL cholesterol have been reported to show positive associations

The authors reported no funding received for this study.

Author disclosures: JAL is Deputy Chair of the UK Government's Scientific Advisory Committee on Nutrition (SACN) and was a member of the SACN's Working Group on "Saturated Fats and Health." JAL chairs the International Life Sciences Institute committee on "Individual Saturated fatty acids and Cardiovascular Risk." BAG reports no conflicts of interest.

Address correspondence to BAG (e-mail: b.griffin@surrey.ac.uk).

with the addition or removal of dietary PUFAs, MUFAs, and SFAs with a chain length of 12–16 carbons (5, 6). The lack of evidence for these associations in this study may reflect a relative weakness in the modeling of observational data as compared with that from intervention trials.

The interpretation of what may seem like a counterintuitive positive association between serum HDL cholesterol and dietary SFA in meta-analyses of RCTs requires consideration of how dietary SFA influences the structure and functional properties of this antiatherogenic lipoprotein. In this respect, associations between macronutrient exchanges and serum HDL cholesterol may be of less value in understanding the link between diet, HDL particles, and ASCVD, in much the same way as the cholesterol content of LDL particles conveys less information about LDL atherogenicity than the number and average size of LDL particles (8). Emerging evidence from studies on the impact of macronutrient composition on the functional properties of HDL is beginning to shed light on mechanistic links with ASCVD (9).

Another point to consider is whether the magnitude of these statistically significant associations, in terms of higher and lower non-HDL cholesterol, is of clinical significance to ASCVD? An increase in non-HDL cholesterol of 1 mg/dL has been reported to be associated with a 5% increased risk of coronary artery disease death in men and women with diabetes, whereas the same change in LDL cholesterol was associated with a lower, 4% increased risk of coronary artery disease death (10). Although diabetes is a disease with a high risk of ASCVD, the higher and lower concentrations of non-HDL cholesterol associated with the replacement of carbohydrate with SFAs (+1.94 mg/dL) and PUFAs (−3.91 mg/dL), respectively, give credibility to the clinical significance of these values.

The study design used carbohydrate as the reference macronutrient in its isoenergetic exchange models. It also claimed that the main findings were reproduced when protein instead of carbohydrate was replaced with dietary fats (data not shown). Although it is possible to interpret the outcome of these dietary exchanges in terms of what might happen when fat is replaced with different fats or carbohydrate, the isoenergetic replacement of SFAs with PUFAs and/or MUFAs would have provided more direct evidence to support the potential benefit of current dietary guidelines to replace SFAs with unsaturated fats. Moreover, the inclusion of data on serum LDL cholesterol would have allowed a direct comparison of the relative efficacy of these dietary exchanges on serum LDL and non-HDL cholesterol. It would also have been possible to estimate remnant lipoprotein cholesterol (total cholesterol minus HDL cholesterol minus LDL cholesterol) as an important atherogenic component of non-HDL cholesterol (11).

Rigor in the choice and application of statistical methods, and the harmonization of data across centers, were listed as major strengths in the present study—in particular, the use of a remote federated analysis (DataSHIELD), which allowed both study-level and virtual individual person data meta-analyses, without the need to pool or share individual-level data. This approach was reported to offer some advantages by reducing governance burdens and ethico-legal challenges.

Limitations of the study include the inevitable drawback of cross-sectional studies producing evidence for associations between macronutrients and serum lipids, rather than causality. Outcomes were also subject to residual confounding, and in coming from just 4 countries may not be representative of the diverse European population. Perhaps more critically, the quality and food sources of macronutrients were not assessed

in this study and are known to exert differential effects on blood lipids and cardiovascular disease risk (12). This includes the quality of carbohydrates, e.g., whole grains compared with simple carbohydrates (13), and dietary fats, e.g., n-6 and n-3 PUFAs (14). It also applies to the differential effects of MUFAs from plants and animals (15), and SFAs from dairy foods and other animal sources (16).

Notwithstanding these and other methodological limitations, the study by Pinart et al. (7) provides indirect evidence to support the benefits of replacing dietary SFAs with unsaturated fats, on serum lipids with greater relevance to cardiometabolic risk than LDL cholesterol.

Acknowledgments

The authors' responsibilities were as follows—both authors equally contributed to all aspects of design and writing of the manuscript and read and approved the final manuscript.

References

1. World Health Organization. Draft guidelines on saturated fatty acid and trans-fatty acid intake for adults and children. Public consultation May to June 2018 [Internet]. Geneva, Switzerland: WHO; 2018 [Accessed: February 26 2021]. Retrieved from: [https://extranet.who.int/dataform/upload/surveys/666752/files/Draft%20WHO%20SFA-TFA%20guidelines_04052018%20Public%20Consultation\(1\).pdf](https://extranet.who.int/dataform/upload/surveys/666752/files/Draft%20WHO%20SFA-TFA%20guidelines_04052018%20Public%20Consultation(1).pdf).
2. Schwab U, Reynolds AN, Sallinen T, Rivellese AA, Risérus U. Dietary fat intakes and cardiovascular disease risk in adults with type 2 diabetes: a systematic review and meta-analysis. *Eur J Nutr* 2021 Feb 21 (Epub ahead of print; doi:10.1007/s00394-021-02507-1).
3. Imamura F, Micha R, Wu JHY, de Oliveira Otto MC, Oti FO, Abioye AI, Mozaffarian D. Effects of saturated fat, polyunsaturated fat, monounsaturated fat, and carbohydrate on glucose-insulin homeostasis: a systematic review and meta-analysis of randomised controlled feeding trials. *PLoS Med* 2016;13:e1002087.
4. Carr SS, Hooper AJ, Sullivan DR, Burnett JR. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. *Pathology* 2019;51: 148–54.
5. Mensink RP, Zock PL, Kester ADM, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. *Am J Clin Nutr* 2003;77(5): 1146–55.
6. Micha R, Mozaffarian D. Saturated fat and cardiometabolic risk factors, coronary heart disease, stroke, and diabetes: a fresh look at the evidence. *Lipids* 2010;45(10):893–905.
7. Pinart M, Jeran S, Boeing H, Stelmach-Mardas M, Standl M, Schulz H, Harris C, von Berg A, Herberth G, Koletzko S, et al. Dietary macronutrient composition in relation to circulating HDL and non-HDL-cholesterol: a federated individual-level analysis of cross-sectional data from adolescents and adults in 8 European studies. *J Nutr* 2021;151(8):2317–29.
8. Bore J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, Daemen MJ, Demer LL, Hegele RA, Nicholls SJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J* 2020;41:2313–30.
9. Hui N, Barter PJ, Ong K-L, Rye K-A. Altered HDL metabolism in metabolic disorders: insights into the therapeutic potential of HDL. *Clin Sci* 2019;133:2221–35.
10. Liu J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. *Diabetes Care* 2005;28:1916–21.
11. Nordestgaard BG, Langlois MR, Langsted A, Chapman MJ, Aarke KM, Baum H, Borén J, Bruckert E, Catapano A, Cobbaert C, et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. *Atherosclerosis* 2020;294:46–61.

12. Astrup A, Magkos F, Bier DM, Brenna JT, de Oliveira Otto MC, Hill JO. Saturated fats and health: a reassessment and proposal for food-based recommendations, *J Am Coll Cardiol* 2020;76:844–57.
13. Li Y, Hruby A, Bernstein AM, Ley SH, Wang DD, Chiuve SE, Sampson L, Rexrode KM, Rimm EB, Willett WC, et al. Saturated fats compared with unsaturated fats and sources of carbohydrates in relation to risk of coronary heart disease: a prospective cohort study. *J Am Coll Cardiol* 2015;66:1538–48.
14. Dias CB, Amigo N, Wood LG, Correig X, Garg ML. Effect of diets rich in either saturated fat or n-6 polyunsaturated fatty acids and supplemented with long-chain n-3 polyunsaturated fatty acids on plasma lipoprotein profiles. *Eur J Clin Nutr* 2017;71:1297–302.
15. Schwingshackl L, Hoffmann G. Monounsaturated fatty acids, olive oil and health status: a systematic review and meta-analysis of cohort studies. *Lipids Health Dis* 2014;13:154.
16. de Oliveira Otto MC, Mozaffarian D, Kromhout D, Bertoni AG, Sibley CT, Jacobs DR, Jr, Nettleton JA. Dietary intake of saturated fat by food source and incident cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. *Am J Clin Nutr* 2012;96:397–404.